During the week, RBI Governor held video conferences with representatives of non-banking financial companies (NBFCs) including NBFC-micro finance institutions (NBFC-MFIs), where issues such as availability of liquidity were discussed.

EBITDA grew by seven per cent as against previous year, to $383 billion. The top-line, though, is down by 12 per cent to $2.7 billion due to lower shipments as well as aluminum prices.

The stock of J B Chemicals & Pharmaceuticals Limited has given a downward sloping trendline breakout on the weekly time frame, formed by connecting swing highs from February 2020. The breakout was supported by strong volumes.

The stock has formed descending hawk candlestick pattern on weekly time frame, which suggest weakening of the short-term uptrend and may reverse to the downtrend after the confirmation candle.

Gold prices went up by 45 per cent in the last year. Is it the right time to invest now?

Active tracking and monitoring of COVID-19 is significant for understanding and curbing its infection vector. For this purpose, Hexaware Technologies came up with a cloud-based, quarantine zone care management software solution called-KareRing. It is a mobile application that provides institutional care providers, a care management dashboard, quarantine zone tracking as well as reporting facility.

On Friday, Biocon announced that United States Food & Drug Administration (USFDA) had issued the company with five observations for its small molecules API manufacturing facility at Biocon Park SEZ, Bommasandra (Bengaluru, Karnataka).

The business also would show high sustainability due to its short-term loans and recovery period of as small as three months, which may not face high risk of defaults due to the current lockdown.

The market opened in the green on May 8, 2020. The previous trading session witnessed the Sensex going down by 0.76 percent to end at 31,443.38 and the Nifty was down 0.78 percent to close at 9,199.05.

Zydus Cadila today informed the bourses that it has launched Enzalutamide, a highly effective drug for the treatment of prostate cancer, under the brand name ‘Obnyx’ in India. With this launch, the treatment cost of prostate cancer is likely to be reduced by almost 70 per cent